Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesRandomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
Journal of Clinical Oncology, 07/01/09
Van Cutsem E et al. - In a trial to investigate whether the addition of irinotecan to the de Gramont infusional fluorouracil (FU)/leucovorin (LV) adjuvant regimen (LV5FU2) would improve disease-free survival (DFS) in pts with stage III colon cancer, it was reported that irinotecan added to LV5FU2 as adjuvant therapy did not confer a statistically significant improvement in DFS or overall survival (OS) in pts with stage III colon cancer vs LV5FU2 alone.
Methods- After curatively intentioned surgery, pts with stage II and III colon cancer were randomly allocated surgery to receive LV5FU2 (LV 200 mg/m2 as 2-hr infusion, followed by FU; as 400 mg/m2 bolus and then 600 mg/m2 continuous infusion over 22 hrs, days 1 and 2, every 2 wks for 12 cycles: de Gramont regimen) with or without irinotecan (180 mg/m2 as 30- to 90-min infusion, day 1, every 2 wks).
- 260 (7.9%) of 3278 pts received an alternative high-dose infusional FU/LV regimen (Arbeitsgemeinschaft Internische Onkologie regimen) with or without irinotecan.
- Principal efficacy analysis was based on 2094 treated pts with stage III disease, randomly allocated in the LV5FU2 strata.
- After median follow-up of 66.3 mos, 5-yr DFS rate was 56.7% with irinotecan/LV5FU2 and 54.3% with LV5FU2 alone.
- Combining irinotecan with LV5FU2 did not significantly improve OS in this pt group vs LV5FU2 alone (5-yr rate 73.6% vs 71.3%, respectively).
- The addition of irinotecan to LV5FU2 was associated with increased incidence of grade 3 to 4 GI events and neutropenia.
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression
Genes, Chromosomes and Cancer, 12/19/09
TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis
Medical Oncology, 12/17/09
A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
Cancer Chemotherapy and Pharmacology, 12/17/09
Sponsor
Article Search
Sponsor
Sponsor